Enaidenib (mesilaat) (Standaard)

Enasidenib (mesylate) (Standard) is the analytical standard of Enasidenib (mesylate) . This product is intended for research and analytical applications. Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes.

1650550-25-6

12352100

Isocitrate Dehydrogenase (IDH) ; Reference Standards

Metabolic Enzyme/Protease; Others

Cancer

CS(=O)(O)=O.CC(O)(C)CNC1=NC(C2=NC(C(F)(F)F)=CC=C2)=NC(NC3=CC(C(F)(F)F)=NC=C3)=N1

C20H21F6N7O4S

569.48

[1]Exploring the Pathway: IDH Mutations and Metabolic Dysregulation in Cancer Cells: A Novel Therapeutic Target. MAY 29, 2015|[2]Alan H. Shih, et al. AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo. Blood 2014 124:437.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-18690AR/

Reference Standards